Vera Therapeutics (VERA) CCO sells 1,582 shares in RSU tax sale

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vera Therapeutics Chief Commercial Officer Laurence Matthew Skelton reported an open-market sale of 1,582 shares of Class A common stock. The shares were sold on February 23, 2026 at a weighted-average price of 41.9839 per share to satisfy tax withholding obligations from vesting restricted stock units.

The sale was executed under the company’s equity incentive plans as a mandated “sell-to-cover” transaction and was not a discretionary trade by Skelton. After this sale, he beneficially owned 64,218 shares of Vera Therapeutics Class A common stock.

Insider Trade Summary

Net Seller: 1,582 shares ($66,419)

Net Sell 1 txn

Insider Skelton Laurence Matthew

Role Chief Commercial Officer

Sold 1,582 shs ($66K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	1,582	$41.9839	$66K

Holdings After Transaction: Class A Common Stock — 64,218 shares (Direct)

Footnotes (1)

The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Form 4 Insider Transactions: What Each Field Means →

02/25/2026 - 07:53 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Skelton Laurence Matthew

(Last)

(First)

(Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE

94005

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	02/23/2026⁽¹⁾	02/24/2026	S⁽²⁾		1,582	D	$41.9839⁽³⁾	64,218	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026.

2. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person.

3. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

	/s/ Joseph R. Young, Attorney-in-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Vera Therapeutics (VERA) report for Laurence Matthew Skelton?

Vera Therapeutics reported that Chief Commercial Officer Laurence Matthew Skelton sold 1,582 shares of Class A common stock. The shares were sold as part of a mandated sell-to-cover transaction tied to tax withholding on vesting restricted stock units.

At what price were the Vera Therapeutics (VERA) shares sold in this Form 4 filing?

The reported weighted-average sale price was 41.9839 per Vera Therapeutics share. Footnotes explain the shares were sold in multiple transactions at prices ranging from 41.005 to 42.84 per share across the covered trading period.

Why did the Vera Therapeutics (VERA) CCO sell 1,582 shares?

The shares were sold solely to satisfy tax withholding obligations arising from vesting restricted stock units. The company’s equity incentive plans required a sell-to-cover transaction, so the sale did not represent a discretionary trade by the reporting person.

How many Vera Therapeutics (VERA) shares does Laurence Matthew Skelton own after the transaction?

Following the reported sale, Laurence Matthew Skelton beneficially owned 64,218 shares of Vera Therapeutics Class A common stock. This figure reflects his direct holdings after the 1,582-share sell-to-cover transaction disclosed in the Form 4 filing.

Over what period were the Vera Therapeutics (VERA) sell-to-cover trades executed?

The trading order for shares sold to cover tax withholding obligations occurred over two business days. According to the footnotes, the activity began on February 23, 2026 and ended on February 24, 2026, covering all participants, including the reporting person.

Were the Vera Therapeutics (VERA) insider sales discretionary trades?

No, the filing states the sales were mandated under the issuer’s equity incentive plans as sell-to-cover transactions. They were executed solely to fund tax withholding obligations from restricted stock unit vesting and did not represent discretionary trading decisions by the insider.